Posted by Michael Wonder on 21 Nov 2018
ICER posts draft scoping document for the assessment of treatments for peanut allergy
20 November 2018 - Document open to public comment until 12 December 2018.
The ICER has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of treatments for peanut allergy. This evidence review will examine two new technologies to induce immune tolerance – Viaskin Peanut (DBV Technologies) and AR101 (Aimmune Therapeutics) – as well as non-commercialised oral immunotherapy (OIT).
On 11 June 2019, ICER’s report will be the subject of a meeting of the California Technology Assessment Forum, one of ICER’s three independent evidence appraisal committees.
